Mibefradil: A selective T-type calcium antagonist

American Journal of Cardiology

Volumn 80, Issue 9 A, 1997, Pages

  Massie Md, Barry M ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; CILAZAPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; MIBEFRADIL; NIFEDIPINE; VERAPAMIL;

CALCIUM ANTAGONISM; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; EXERCISE TOLERANCE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INOTROPISM; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANGINA PECTORIS; ANIMALS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MIBEFRADIL; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES;

EID: 0030779617     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Wood AJJ. Calcium antagonists. Pharmacologic differences and similarities. Circulation. 80:(suppl IV):1989;IV-184-IV-188.
2. Bakx ALM, van der Wall EE, Braun S, Emanuelsson H, Bruschke AVG, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris a multicenter, placebo-controlled study . Am Heart J. 130:1995;748-757.
3. Bernink PJLM, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967). A new generation of calcium antagonists? Hypertension. 27:1996;426-432.
4. Braun S, van der Wall EE, Emanuelsson H, Kobrin I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with chronic stable angina pectoris a multicenter placebo-controlled study . J Am Coll Cardiol. 27:1996;317-322.
5. Clozel J-P, Osterrieder W, Kleinbloesem CH, Welker HA, Schläppi B Tudor R, Hefti F, Schmitt R, Eggers H. Ro 40-5967 a new nondihydropyridine calcium antagonist . Cardiovasc Drug Rev. 9:1991;4-17.
6. Levine TB. The design of the mortality assessment in congestive heart failure trial (MACH-1, mibefradil). Clin Cardiol. 20:1997;320-326.
7. Mulder P, Richard V, Compagnon P, Henry J-P, Lallemand F, Clozel J-P, Koen R, Macé B, Thuillez C. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol. 29:1997;416-421.
8. Triggle DJ. Pharmacologic and therapeutic differences among calcium channel antagonists profile of mibefradil, a new calcium antagonist . Am J Cardiol. 78:(suppl 9A):1996;7-12.
9. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol. 13:1989;754-759.
10. 2+ channel in cardiac tissue. Eur J Pharmacol. 280:1995;155-158.
11. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther. 4:1990;731-736.
12. Portegies MCM, Schmitt R, Kraaij CJ, Braat SHJG, Gassner A, Hagemeijer F, Pozenel H, Prager G, Viersma JW, van der Wall EE, Kleinbloesem CH, Lie KI. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol. 18:1991;746-751.
13. Oparil S, Kobrin I, Abernethy DR, Levine BS, Reif MC, Shepherd AM. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997; (In press).
14. 2+ channels by Ro 40-5967. Circ Res. 75:1994;144-148.
15. 2+ signaling in the cardiovascular system. Am J Cardiol. 78:(suppl 9A):1996;2-6.
16. Katz AM. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol. 28:1996;522-529.
17. Hermsmeyer K, Mishra S, Miyagawa K, Minshall R. Physiological and pathophysiological relevance of T-type calcium channels potential indications for T-type calcium antagonists . Clin Ther. 19:(suppl A):1997;18-26.
18. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 73:1993;777-782.
19. Clozel J-P, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs comparison with verapamil . J Cardiovasc Pharmacol. 14:1989;713-721.
20. Kaplan NM. Calcium entry blockers in the treatment of hypertension. Current status and future prospects. JAMA. 262:1989;817-823.
21. Frishman WH, Stroh JA, Greenberg S, Suarez T, Karp A, Peled H. Calcium channel blockers in systemic hypertension. Med Clin North Am. 72:1988;449-499.
22. Calan (verapamil hydrochloride) tablets prescribing information. Physicians' Desk Reference. 51st ed. 1997;2568-2574 Medical Economics Company, Montvale, NJ.
23. Cardizem CD (diltiazem hydrochloride) capsules prescribing information. Physicians' Desk Reference. 51st ed. 1997;1251-1253 Medical Economics Company, Montvale, NJ.
24. Norvasc (amlodipine besylate) tablets prescribing information. Physicians' Desk Reference. 51st ed. 1997;2020-2022 Medical Economics Company, Montvale, NJ.
25. Procardia XL (nifedipine) extended release tablets prescribing information. Physicians' Desk Reference. 51st ed. 1997;2026-2028 Medical Economics Company, Montvale, NJ.
26. 2+ inward currents by Ro 40-5967 and verapamil relation to negative inotropy . Eur J Pharmacol. 196:1991;205-207.
27. Nelson MT, Patlak JB, Worley JF, Standen NB. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol. 259:1990;C3-C18.
28. Schmitt R, Kleinbloesem CH, Belz GG, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez A-JJ Welker HA, van Brummelen P. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 52:1992;314-323.
29. Schmitt R, Clozel J-P, Iberg N, Bühler FR. Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol. 15:1995;1161-1165.
30. Gray GA, Clozel M, Clozel J-P, Baumgartner H-R. Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats. Hypertension. 22:1993;569-576.
31. Lüscher TF, Clozel J-P, Noll G. Pharmacology of the calcium antagonist mibefradil. J Hypertens. 15:(supp 3):1997;S11-S18.
32. Viskoper RJ, Bernink PJLM, Ziekenhuis M, Schelling A, Ribeiro AB, Kantola IM, Wilkins MR, Kobrin I. A randomized, double-blind trial comparing mibefradil and amlodipine two long-acting calcium antagonists with similar efficacy but different tolerability profiles . J Hum Hypertens. 11:1997;387-393.
33. Massie BM, Chrysant SG, Jain A, Weir M, Weiss R, Kobrin I. Antihypertensive effects of mibefradil a double-blind comparison with diltiazem CD . Clin Cardiol. 20:1997;562-568.
34. Lacourcière Y, Poirier L, Lefebvre J, Archambault F, Ave SD, Ward C, Lindberg E. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Am J Hypertens. 10:1997;189-196.
35. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires JA, Kobrin I. Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. Circulation 1997; (In press).
36. Davies GJ, Kobrin I, Caspi A, Reisin LH, de Albuquerque DC, Armagnijan D, Coelho OR, Schneeweiss A. Long-term anti-anginal and anti-ischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with diltiazem SR. Am Heart J 1997; (In press).